Appili Therapeutics, Inc. (APLIF)
0.0055
0.00 (0.00%)
USD |
OTCM |
Oct 16, 16:00
Appili Therapeutics Max Drawdown (5Y) : 99.27% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.27% |
| August 31, 2026 | 99.27% |
| July 31, 2026 | 99.27% |
| June 30, 2026 | 99.27% |
| May 31, 2026 | 99.27% |
| April 30, 2026 | 99.27% |
| March 31, 2026 | 99.27% |
| February 28, 2026 | 99.27% |
| January 31, 2026 | 99.27% |
| December 31, 2025 | 99.27% |
| November 30, 2025 | 99.27% |
| October 31, 2025 | 99.27% |
| September 30, 2025 | 99.27% |
| August 31, 2025 | 99.27% |
| July 31, 2025 | 99.27% |
| June 30, 2025 | 99.16% |
| May 31, 2025 | 99.09% |
| April 30, 2025 | 98.98% |
| March 31, 2025 | 98.98% |
| February 28, 2025 | 98.98% |
| January 31, 2025 | 98.98% |
| December 31, 2024 | 98.98% |
| November 30, 2024 | 98.98% |
| October 31, 2024 | 98.98% |
| September 30, 2024 | 98.78% |
| Date | Value |
|---|---|
| August 31, 2024 | 98.78% |
| July 31, 2024 | 98.78% |
| June 30, 2024 | 98.78% |
| May 31, 2024 | 98.78% |
| April 30, 2024 | 98.78% |
| March 31, 2024 | 98.78% |
| February 29, 2024 | 98.78% |
| January 31, 2024 | 98.77% |
| December 31, 2023 | 98.38% |
| November 30, 2023 | 98.38% |
| October 31, 2023 | 98.38% |
| September 30, 2023 | 98.34% |
| August 31, 2023 | 98.34% |
| July 31, 2023 | 98.34% |
| June 30, 2023 | 98.34% |
| May 31, 2023 | 98.12% |
| April 30, 2023 | 98.12% |
| March 31, 2023 | 98.12% |
| February 28, 2023 | 98.06% |
| January 31, 2023 | 98.06% |
| December 31, 2022 | 98.06% |
| November 30, 2022 | 98.06% |
| October 31, 2022 | 97.59% |
| September 30, 2022 | 97.06% |
| August 31, 2022 | 96.58% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| InMed Pharmaceuticals, Inc. | 99.97% |
| NervGen Pharma Corp. | 73.37% |
| Milestone Pharmaceuticals, Inc. | 95.25% |
| Clearmind Medicine, Inc. | -- |
| Lexaria Bioscience Corp. | 99.02% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -67.50 |
| Beta (5Y) | 0.1484 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 90.88% |
| Historical Sharpe Ratio (5Y) | -0.7264 |
| Historical Sortino (5Y) | -1.274 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 34.85% |